Human Immunodeficiency Virus Infection — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for human immunodeficiency virus infection. 103 active patents protecting 8 drugs from 6+ originators. First major cliff: 2032. Daily refresh.

8
Approved drugs
103
Active US patents
64/100
Avg vulnerability
$2.4B
Annual revenue covered

Originators in Human Immunodeficiency Virus Infection

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Gilead Sciences 79 patents Janssen Prods 14 patents Merck & Co. 4 patents Bristol-Myers Squibb 3 patents GSK 2 patents Boehringer Ingelheim 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating human immunodeficiency virus infection. Each bar = one year. Y-axis scaled to peak year (24 patents).

24
26
21
27
13
29
10
30
19
32
13
33
2
36
1
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tybost
COBICISTAT
 Gilead Sciences 54 46 — 2026-08-27
Prezista
DARUNAVIR
 Janssen Prods 14 51 — 2026-12-26
Emtriva
EMTRICITABINE
 Gilead Sciences 13 62 $2.4B 2032-08-15
Vitekta
ELVITEGRAVIR
 Gilead Sciences 12 72 — 2026-08-27
Pifeltro
DORAVIRINE
 Merck & Co. 4 52 — 2032-08-30
Sustiva
EFAVIRENZ
 Bristol-Myers Squibb 3 73 — 2026-06-13
Epivir
LAMIVUDINE
 GSK 2 72 — 2029-03-11
Viramune
NEVIRAPINE
 Boehringer Ingelheim 1 80 — 2029-03-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7176220 Vitekta method of use 85 2026-08-27
7176220 Vitekta method of use 85 2026-08-27
7635704 Vitekta method of use 85 2026-10-26
7635704 Vitekta method of use 85 2026-10-26
9545414 Sustiva method of use 80 2026-06-13
9018192 Sustiva method of use 80 2026-06-13
7176220 Vitekta other 80 2027-02-27
7176220 Vitekta other 80 2027-02-27
7635704 Vitekta other 80 2027-04-26
8981103 Vitekta other 80 2027-04-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7700645 Tybost composition of matter 5 2026-12-26
7700645 Tybost composition of matter 5 2026-12-26
8981103 Tybost composition of matter 5 2026-10-26
8981103 Tybost composition of matter 5 2026-10-26
7700645 Tybost composition of matter 18 2026-12-26
8981103 Vitekta composition of matter 22 2026-10-26
8981103 Vitekta composition of matter 22 2026-10-26
10039718 Tybost formulation 25 2032-10-06
10039718 Tybost formulation 25 2032-10-06
10039718 Tybost formulation 25 2032-10-06

Related